Impact of de novo donor‐specific HLA antibodies detected by Luminex solid‐phase assay after transplantation in a group of 88 consecutive living‐donor renal transplantations. (14th November 2013)

• Record Type: Journal Article
• Authors: Dieplinger, Georg; Ditt, Vanessa; Arns, Wolfgang; Huppertz, Andrea; Kisner, Tuelay; Hellmich, Martin; Bauerfeind, Ursula; Stippel, Dirk L.
• Is Part Of: Transplant international. Volume 27:Number 1(2014:Jan.)
• Page Start: 60
• Page End: 68
• Publication Date: 2013-11-14
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95405
• DOI: 10.1111/tri.12207
• Languages: English
• ISSNs: 0934-0874

Abstract

<abstract abstract-type="main" id="tri12207-abs-0001"> <title>Summary</title> <p> <italic>De novo</italic> donor‐specific HLA antibodies (DSA) after renal transplantation are known to be correlated with poor graft outcome and the development of acute and chronic rejection. Currently, data for the influence of <italic>de novo</italic> DSA in patient cohorts including only living‐donor renal transplantations (LDRT) are limited. A consecutive cohort of 88 LDRT was tested for the occurrence of <italic>de novo</italic> DSA by utilizing the highly sensitive Luminex solid‐phase assay for antibody detection. Data were analyzed for risk factors for <italic>de novo</italic> DSA development and correlated with acute rejection (AR) and graft function. Patients with <italic>de novo</italic> DSA [31 (35%)] showed a trend for inferior graft function [mean creatinine change (mg/dL/year) after the first year: 0.15 DSA (+) vs. 0.02 DSA (−) (<italic>P </italic>=<italic> </italic>0.10)] and a higher rate of AR episodes, especially in case of <italic>de novo</italic> DSA of both class I and II [6 (55%), (<italic>P </italic>=<italic> </italic>0.05)]. Antibody‐mediated rejection (AMR) appeared in five patients and was significantly correlated with <italic>de novo</italic> DSA (<italic>P </italic>=<italic> </italic>0.05). Monitoring for <italic>de novo</italic> DSA after LDRT may help to identify patients at risk of declining renal function. Especially patients with simultaneous presence of <italic>de novo</italic> DSA class I and class II are at a high risk to suffer AR episodes.</p> </abstract>